|
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 2819-2827.
Prepublished online as a Blood First Edition Paper on June 25, 2007; DOI 10.1182/blood-2007-03-077792.
 Previous Article | Next Article 
Submitted March 5, 2007
Accepted June 21, 2007
Galectins in the tumor endothelium; opportunities for combined cancer therapy
Victor LJL Thijssen, Francoise Poirier, Linda G. Baum, and Arjan W Griffioen*
Department of Pathology, Angiogenesis Laboratory, Research Institute for Growth & Development, University Maastricht & Academic Hospital Maastricht, Maastricht, Netherlands
Institute Jacques Monod, Univ. P6 and P7, Paris, France
Department of Pathology and Laboratory Medicine, University of California, School of Medicine, Los Angeles, CA, United States
* Corresponding author; email: aw.griffioen{at}path.unimaas.nl.
Galectins are emerging as a family of proteins that play an important role in several steps of tumorigenesis. Evidence is accumulating that galectins are expressed by the tumor endothelium where they contribute to different steps of tumor progression like immune escape and metastasis. Recent studies have identified an important role for galectins in tumor angiogenesis. Moreover, it has been shown that galectins in the endothelium can be targeted for therapeutic applications. This opens a window of opportunities for the development of tumor-type independent treatment strategies. This review focuses on the expression of galectins in the tumor endothelium, their contribution to tumor progression, and their application in tumor-type independent cancer therapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. V Norling, M. Perretti, and D. Cooper
Endogenous galectins and the control of the host inflammatory response
J. Endocrinol.,
May 1, 2009;
201(2):
169 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Loser, A. Sturm, M. Voskort, V. Kupas, S. Balkow, M. Auriemma, C. Sternemann, A. U. Dignass, T. A. Luger, and S. Beissert
Galectin-2 Suppresses Contact Allergy by Inducing Apoptosis in Activated CD8+ T Cells
J. Immunol.,
May 1, 2009;
182(9):
5419 - 5429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. SAUSSEZ, C. DECAESTECKER, S. CLUDTS, P. ERNOUX, D. CHEVALIER, K. SMETANA Jr., S. ANDRE, X. LEROY, and H.-J. GABIUS
Adhesion/Growth-regulatory Tissue Lectin Galectin-1 in Relation to Angiogenesis/Lymphocyte Infiltration and Prognostic Relevance of Stromal Up-regulation in Laryngeal Carcinomas
Anticancer Res,
January 1, 2009;
29(1):
59 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gendronneau, S. S. Sidhu, D. Delacour, T. Dang, C. Calonne, D. Houzelstein, T. Magnaldo, and F. Poirier
Galectin-7 in the Control of Epidermal Homeostasis after Injury
Mol. Biol. Cell,
December 1, 2008;
19(12):
5541 - 5549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. W. Grubb, C. Murdoch, P. E. Sudbery, S. P. Saville, J. L. Lopez-Ribot, and M. H. Thornhill
Candida albicans-Endothelial Cell Interactions: a Key Step in the Pathogenesis of Systemic Candidiasis
Infect. Immun.,
October 1, 2008;
76(10):
4370 - 4377.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cederfur, E. Salomonsson, J. Nilsson, A. Halim, C. T Oberg, G. Larson, U. J Nilsson, and H. Leffler
Different affinity of galectins for human serum glycoproteins: Galectin-3 binds many protease inhibitors and acute phase proteins
Glycobiology,
May 1, 2008;
18(5):
384 - 394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. L. Thijssen, S. Hulsmans, and A. W. Griffioen
The Galectin Profile of the Endothelium: Altered Expression and Localization in Activated and Tumor Endothelial Cells
Am. J. Pathol.,
February 1, 2008;
172(2):
545 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
